Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 25.6% during trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.27. Approximately 1,058,771 shares were traded during mid-day trading, an increase of 65% from the average daily volume of 640,063 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Up 25.6 %
The company has a market capitalization of C$23.52 million, a P/E ratio of -13.50 and a beta of 0.20. The business has a 50 day moving average of C$0.10 and a 200 day moving average of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Why Are These Companies Considered Blue Chips?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Top Biotech Stocks: Exploring Innovation Opportunities
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Manufacturing Stocks Investing
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
